The 13th UK Stroke Forum Conference took place at The International Centre, Telford, from 4 - 6 December 2018.
This three-day multidisciplinary conference brought together over 110 expert speakers and researchers, all committed to improving stroke care.
The conference proves to be a huge success each year with 99% of attendees saying they would recommend it to others.
Sign up to our mailing list to be the first to receive information about the UK Stroke Forum and exclusive early access to tickets for the 2019 UK Stroke Forum Conference.
UKSF 2018 programmes
You can review our 2018 preliminary programme and at a glance programme now.
The 2018 conference also included sessions on primary care training, stroke research and nursing and rehab workshops.
- Primary Care Training Stream Programme
- Stroke Research Training Day Programme
- Nursing and Rehab Workshop Schedule
Training stream 1
Dr Ajay Bhalla - Evidence-based update (2018) for stroke physicians
Review of Important Stroke Trials 2018
Training Stream 3
Cath Curley and Clare Gordon - Early physiological changes and actions
Dr Viki Teggart and Dr Natalie Arran - Cognitive rehabilitation for everyone - embedding enhanced learning techniques into your practice
Plenary 1
Professor Martin Dennis - Does a six month course of Fluoxetine improve recovery after stroke? Results of the Fluoxetine Or Control Under Supervision (FOCUS) trial
Parallel session 1B
Professor Gary Ford - To drip or ship: a UK perspective
Professor Keith Muir - Reperfusion therapies today and tomorrow
Primary Care workshop - Long Term Care
Charlotte Emmett - Assessing mental capacity in people with communication problems
Parallel session 2C
Verity Longley - Do people with pre-existing cognitive impairments receive less stroke rehabilitation?
Parallel Session 3B
Dr Kate Radford - Vocational rehabilitation & return to work after stroke
Parallel session 3C
Professor Jon Marsden - Gait training to improve balance
Parallel session 3D
Chris Ashton - Adherence to the pre-hospital stroke pathway in Greater Manchester
Dr Nadia Allan - Time to Stroke Unit - reducing delays and barriers
Parallel 4C
Lisa Everton - Swallowing therapy for dysphagia in acute and subacute stroke: Review - Cochrane Collaboration
Dr David Seiffge - Ischaemic stroke despite oral anticoagulant therapy in patients with AF - what is the risk of recurrent events and how to prevent further events?
We are delighted that the World Stroke Organisation and European Stroke Organisation endorsed the UK Stroke Forum Conference 2018.
UKSF 2018 sponsors and partners
We would like to extend our thanks to our 2018 sponsors and partners:
Gold Sponsor - Pfizer Ltd on behalf of the BMS-Pfizer Alliance
About the Bristol-Myers Squibb/Pfizer Collaboration
In 2007, Pfizer and Bristol-Myers Squibb entered into a worldwide collaboration to develop and commercialise apixaban, an oral anticoagulant discovered by Bristol-Myers Squibb. This global alliance combines Bristol-Myers Squibb's long-standing strengths in cardiovascular drug development and commercialisation with Pfizer's global scale and expertise in this field.
About Bristol-Myers Squibb
Bristol-Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information, please visit http://www.bms.co.uk
Pfizer Ltd.: Working together for a healthier worldâ„¢
At Pfizer, we apply science and our global resources to improve health and well-being at every stage of life. We strive to set the standard for quality, safety and value in the discovery, development and manufacturing of medicines. Our diversified global health care portfolio includes medicines and vaccines, as well as many of the world's best-known consumer healthcare products. Every day, Pfizer colleagues work to advance wellness, prevention, treatments and cures that challenge the most feared diseases of our time. Consistent with our responsibility as one of the world's premier innovative biopharmaceutical companies, we also collaborate with health care providers, governments and local communities to support and expand access to reliable, affordable health care around the world. For more than 150 years, Pfizer has worked to make a difference for all who rely on us. In the UK, Pfizer has its business headquarters in Surrey and is a major supplier of medicines to the NHS.
Amgen is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology.
Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people's lives. A biotechnology pioneer since 1980, Amgen has grown to be one of the world's leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential.
A dedicated and highly focused company, specialising in the sale and support of the most innovative and cost effective Ambulatory Patient Monitoring Systems.
Automatic Arrhythmia Detection Devices, AF Screening, Arrhythmia Screening, Holter Monitoring and Blood Pressure Monitoring.
Please visit us at stand number A7 to find out more.
Through our innovative mechanism of non-invasive neuromuscular electrostimulation we have developed a ground-breaking NMES technology platform, OnPulseâ„¢, embedded in our industry-leading brand, the gekoâ„¢ device. Our range of non-invasive gekoâ„¢ products are wearable therapy devices tailored to different medical applications, selling both direct and through partnerships and distributors in each clinical area. Clinical areas of interest include the prevention of venous thromboembolism (VTE), in particular acute stroke, the prevention and reduction of oedema and wound healing.
CaptureStroke is the UK's market leading Stroke clinical pathway software, enabling clinicians to deliver best evidence-based Stroke care and giving NHS Trusts complete ownership of their data. Going beyond standard SSNAP reporting to promote a culture of safety and quality, CaptureStroke provides real-time analytics and care alerts in addition to an at-a-glance status of all Stroke patients across the Trust.
Complementing and integrating with a wide range of EPR/PAS systems, CaptureStroke's imbedded clinical protocols enable clinicians to easily adhere to the NHS RightCare Stroke pathway, and current developments include a patient focused Stroke Digital Passport.
CaptureStroke allows clinicians to interact with their data to enable service improvement and monitor key performance indicators with ease, leading to increased tariff performance and improved patient outcomes.
Stryker NV is focused on advancing the practice of less invasive stroke therapies through its Complete Stroke Care solutions. Stryker is dedicated to providing innovative stroke products and services for ischemic and hemorrhagic stroke, and committed to providing clinical education and support to help physicians deliver better patient outcomes. Products include: stent retriever, detachable coils, stents, balloons, guidewires and microcatheters.
Keep in touch
You can follow us on Twitter @ukstrokeforum, #UKSF18